Verona Pharma PLC | Ownership
Companies that own Verona Pharma PLC
Aviva Investors Global Services Ltd.
3,278,448
3.31%
-342,404
0.01%
05/03/2017
Hargreave Hale Ltd.
3,107,001
3.14%
136,000
0.05%
06/01/2018
Polar Capital LLP
3,000,000
3.03%
0
0.01%
07/31/2018
FIL Investment Advisors (UK) Ltd.
1,769,952
1.79%
-40
0%
03/31/2018
Tekla Capital Management LLC
1,442,478
1.46%
0
0.08%
03/31/2018
Hargreaves Lansdown Asset Management Ltd.
1,104,000
1.12%
-15,000
0.02%
06/01/2018
Jarvis Investment Management Ltd.
938,000
0.95%
-192,000
0.12%
06/01/2018
Talos Securities Ltd.
285,000
0.28%
-65,000
0.41%
06/01/2018
HSBC Global Asset Management (UK) Ltd.
282,000
0.28%
-9,000
0%
06/01/2018
Smith & Williamson Investment Management LLP
207,000
0.21%
-137,000
0.01%
06/01/2018
| Address |
3 More London Riverside
London Greater London SE1 2RE
United Kingdom
|
|
Employees
|
- |
| Website |
http://veronapharma.com |
| Updated |
07/08/2019 |
| Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. |
